CLEO DIAGNOSTICS LTD - News & Media

8.11%

40.0¢

Market Cap $32.64M

Healthcare Medical Care

Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal... Cleo Diagnostics Limited is an ovarian cancer diagnostics company. Its principal activities involve the development and patent of a blood test for the detection of ovarian cancer. It focuses on bringing to market a blood test for the early diagnosis of ovarian cancer based on the novel CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is absent in non-malignant disease. It is advancing the availability of its blood test, under a modular execution strategy, which is designed to address all ovarian cancer detection markets with specific tests, including surgical triage, recurrence, high risk, and early-stage screening. Triage Test is a pre-surgical test to determine ovarian or adnexal mass for which surgical referral is required who have not yet been referred to an oncologist.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Articles & Videos

CLEO Diagnostics kicks off IP transfer for ovarian cancer blood tests to US manufacturers

CLEO Diagnostics has commenced the 'technology transfer' process to a US-based manufacturing partner ahead of commercialisation.

18 Mar 2025 12:24 (AEDT)

Cleo adds Royal Women's Hospital to its clinical trial for ovarian cancer diagnosis

Cleo Diagnostics Ltd has expanded its clinical trial for a blood test to detect ovarian cancer, with the addition of the hospital

27 Nov 2024 10:23 (AEDT)

CLEO Diagnostics kicks off ovarian cancer-detecting blood test trials in USA

Cleo Diagnostics (ASX:COV) has revealed it's kicked off US-based trials sussing the reliability of its blood tests designed to detect ovarian cancer.

06 Sep 2024 09:22 (AEST)

Cleo kicks off long path towards FDA approval for ovarian cancer blood tests

Cleo Diagnostics has announced it's commenced the FDA regulatory process to get into the US market with its ovarian cancer test kit.

26 Jun 2024 09:55 (AEST)

Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.The company @ developing a blood test to detect ovarian cancer as opposed to relying on ultrasound @ has declared its blood tests detected 90% of early-stage cancers in participating pati...

29 May 2024 10:36 (AEST)

Early-stage ovarian cancer researcher Cleo Diagnostics (ASX:COV) makes ASX debut after $12m IPO

Early-stage ovarian cancer researcher Cleo Diagnostics is making its ASX debut today following an IPO where it raised $12 million.

22 Aug 2023 14:59 (AEST)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 40.0¢		Change 0.030(8.11%)		Mkt cap ! $32.64M

Open	High	Low	Value	Volume
37.0¢	40.0¢	37.0¢	$33.65K	86.60K

Buyers (Bids)

No.	Vol.	Price($)
2	16950	37.5¢

Sellers (Offers)

Price($)	Vol.	No.
40.0¢	26783	2

View Market Depth

No.	Vol.	Price($)
2	16950	0.375
1	20000	0.370
3	80912	0.365
1	8336	0.360
2	28000	0.350

Price($)	Vol.	No.
0.400	26783	2
0.405	25000	1
0.410	49119	2
0.415	33124	1
0.420	82092	2

Last trade - 14.18pm 30/07/2025 (20 minute delay)


Last 38.5¢		Change 0.030 ( 5.48 %)
Open	High	Low	Volume
37.0¢	38.5¢	37.0¢	39680
Last updated 10.21am 30/07/2025 ?

COV (ASX) Chart